Fig 1.
Diagram of study participants and blood samples pre-vaccine, 30–45 days and 1 year after vaccination.
The collections are not exclusive, that is, individuals who missed a follow-up contact were still eligible for subsequent blood collections.
Table 1.
Sociodemographic and pre-vaccination status for yellow fever, dengue and Zika by age group.
Fig 2.
Percentage and 95% confidence intervals of yellow fever seroconversion 30–45 days and 1 year after vaccination by age range.
Pre-vaccine yellow fever seropositive individuals excluded.
Fig 3.
Geometric means and 95% confidence intervals of yellow fever antibody titers (reciprocal of dilution) 30–45 days and 1 year after vaccination by age range.
Pre-vaccine yellow fever seropositive individuals excluded.
Table 2.
Distribution of children (between 9 months and 4 years) by serological status for yellow fever 30–45 days after vaccination, stratified by pre-vaccine serological status (neutralizing antibodies) for dengue and Zika.
Table 3.
Distribution of adults (between 18 and 50 years) by serological status for Yellow Fever 30–45 days after vaccination, stratified by pre-vaccine serological status (neutralizing antibodies) for dengue and Zika.
Table 4.
Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in children (between 9 months and 4 years) (n = 2,328).
Table 5.
Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 1,504).
Table 6.
Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in children (between 9 months and 4 years) (n = 339).
Table 7.
Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 240).